pharma · Polycythemia Vera (PV) · Primary Myelofibrosis
PharmaEssentia
PharmaEssentia is a pharma organization headquartered in CN. Primary therapeutic focus areas include Polycythemia Vera (PV), Primary Myelofibrosis. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 pat
Burlington, USA HQ
2003 Founded
356 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Burlington, USA
- Founded
- 2003
- Employees
- 356
- Programs
- 2
- Drugs
- 3
- Patents
- 0
Ropeginterferon alfa-2b
Phase 3 · mab · Primary Myelofibrosis
Ropeginterferon alfa-2b for Primary Myelofibrosis is a Phase 3 program (mab) at PharmaEssentia with 1 ClinicalTrials.gov record(s).
Internal code A23-302
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- PharmaEssentia
- Phase
- Phase 3
- Modality
- mab
- Indication
- Primary Myelofibrosis
- Status
- active
- Trials
- 1